106 related articles for article (PubMed ID: 15814740)
1. CD4+ T cell responses to SSX-4 in melanoma patients.
Ayyoub M; Merlo A; Hesdorffer CS; Rimoldi D; Speiser D; Cerottini JC; Chen YT; Old LJ; Stevanovic S; Valmori D
J Immunol; 2005 Apr; 174(8):5092-9. PubMed ID: 15814740
[TBL] [Abstract][Full Text] [Related]
2. Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.
Godefroy E; Wang Y; Souleimanian NE; Scotto L; Stevanovic S; Chen YT; Valmori D; Ayyoub M
Cancer Immunol Immunother; 2007 Aug; 56(8):1183-92. PubMed ID: 17186289
[TBL] [Abstract][Full Text] [Related]
3. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.
Valmori D; Qian F; Ayyoub M; Renner C; Merlo A; Gnjatic S; Stockert E; Driscoll D; Lele S; Old LJ; Odunsi K
Clin Cancer Res; 2006 Jan; 12(2):398-404. PubMed ID: 16428478
[TBL] [Abstract][Full Text] [Related]
4. Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.
Ayyoub M; Hesdorffer CS; Metthez G; Stevanovic S; Ritter G; Chen YT; Old LJ; Speiser D; Cerottini JC; Valmori D
J Immunol; 2004 Jun; 172(11):7206-11. PubMed ID: 15153546
[TBL] [Abstract][Full Text] [Related]
5. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
Ayyoub M; Stevanovic S; Sahin U; Guillaume P; Servis C; Rimoldi D; Valmori D; Romero P; Cerottini JC; Rammensee HG; Pfreundschuh M; Speiser D; Lévy F
J Immunol; 2002 Feb; 168(4):1717-22. PubMed ID: 11823502
[TBL] [Abstract][Full Text] [Related]
6. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.
Ayyoub M; Merlo A; Hesdorffer CS; Speiser D; Rimoldi D; Cerottini JC; Ritter G; Chen YT; Old LJ; Stevanovic S; Valmori D
Clin Immunol; 2005 Jan; 114(1):70-8. PubMed ID: 15596411
[TBL] [Abstract][Full Text] [Related]
7. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.
Ayyoub M; Hesdorffer CS; Montes M; Merlo A; Speiser D; Rimoldi D; Cerottini JC; Ritter G; Scanlan M; Old LJ; Valmori D
J Clin Invest; 2004 Apr; 113(8):1225-33. PubMed ID: 15085202
[TBL] [Abstract][Full Text] [Related]
8. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.
Smith HA; Cronk RJ; Lang JM; McNeel DG
Cancer Res; 2011 Nov; 71(21):6785-95. PubMed ID: 21880588
[TBL] [Abstract][Full Text] [Related]
9. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.
He Y; Mao L; Lin Z; Deng Y; Tang Y; Jiang M; Li W; Jia Z; Wang J; Ni B; Wu Y
Mol Immunol; 2008 May; 45(9):2455-64. PubMed ID: 18295890
[TBL] [Abstract][Full Text] [Related]
10. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
[TBL] [Abstract][Full Text] [Related]
11. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines.
dos Santos NR; Torensma R; de Vries TJ; Schreurs MW; de Bruijn DR; Kater-Baats E; Ruiter DJ; Adema GJ; van Muijen GN; van Kessel AG
Cancer Res; 2000 Mar; 60(6):1654-62. PubMed ID: 10749136
[TBL] [Abstract][Full Text] [Related]
13. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
14. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
[TBL] [Abstract][Full Text] [Related]
15. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
[TBL] [Abstract][Full Text] [Related]
16. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
[TBL] [Abstract][Full Text] [Related]
17. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles.
Godefroy E; Scotto L; Souleimanian NE; Ritter G; Old LJ; Jotereau F; Valmori D; Ayyoub M
Clin Immunol; 2006 Oct; 121(1):54-62. PubMed ID: 16814609
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
19. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.
Nuber N; Curioni-Fontecedro A; Matter C; Soldini D; Tiercy JM; von Boehmer L; Moch H; Dummer R; Knuth A; van den Broek M
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15187-92. PubMed ID: 20696919
[TBL] [Abstract][Full Text] [Related]
20. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
